New Data Scheduled for Presentation on Daxor’s BVA-100®
NEW YORK – February 12, 2020 – Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the Society for Critical Care Medicine (SCCM) 49th Congress at the Orlando Convention Center in Orlando, FL, from February 16-18th, 2019. Research from the University of Hawaii – John A. Burns School of Medicine relating to the use of Daxor’s BVA-100 (Blood Volume Analyzer) diagnostic test in critical care use is scheduled to be presented.
“The SCCM gathers more than 6,000 critical care professionals from around the world to share ideas and seek solutions to improve outcomes in the critically ill. In a peer-reviewed randomized control trial, the BVA test showed that optimization of intravascular blood volume led to a 44% change in treatment decisions, improves outcomes, length of stay, and can reduce mortality by up to 66% versus conventional therapy in complex critically-ill patients. We look forward to sharing with leaders new data on how precise, individualized fluid management can lead to better patient outcomes,” said Michael Feldschuh, CEO of Daxor Corporation. The company will be exhibiting at Booth #902.
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions including heart failure and critical care by better informing treatment strategies, resulting in significantly better patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information please visit our website at https://www.daxor.com.
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Sr. Managing Partner, CORE IR